Structure-Based Virtual Screening of Novel Allosteric Inhibitors Targeting KRAS G12D: Molecular Dynamics and Binding Free Energy Analysis
DOI:
https://doi.org/10.5281/zenodo.22664526Keywords:
KRAS G12D, allosteric inhibitor, virtual screening, molecular dynamics, binding free energyAbstract
Background: KRAS G12D is the most frequent KRAS lesion in pancreatic and colorectal cancer, yet it has long resisted
small-molecule targeting because it lacks the reactive cysteine that made covalent G12C inhibitors possible and offers a nucleotide
pocket with no obvious ligandable groove.
Objective: This review synthesizes the published literature on structure-based virtual screening, molecular dynamics (MD)
simulation, and binding free energy calculation as applied to the discovery of allosteric KRAS G12D inhibitors, situating this work
against the methodological precedent set by G12C-directed covalent inhibitors.
Scope: We cover the switch I/switch II allosteric pocket biology that underlies current design strategies, docking and
pharmacophore-based virtual screening approaches, MD protocols used to validate and refine binding poses, and end-point
(MM-GBSA/MM-PBSA) versus alchemical (free energy perturbation) methods for ranking candidate affinity. Case studies include
the noncovalent inhibitor MRTX1133, salt-bridge-forming analogs, the targeted degrader ASP3082, and the SOS1 inhibitor BI-3406
as a pathway-adjacent strategy.
Conclusions: Computational structure-based methods have been central, not incidental, to converting KRAS G12D from an
undruggable target into one with an advanced noncovalent clinical candidate. Persisting limitations include narrow structural
diversity across screening pipelines built on a single co-crystal template, uncertainty in end-point free energy estimates within this
polar, solvent-exposed pocket, and limited systematic application of rigorous alchemical free energy methods at the hit-finding
stage. Extending accurate free energy estimation earlier in the discovery funnel, and adapting computational pipelines to
ternary-complex and protein-protein-interface targeting strategies, are identified as priorities for the next phase of KRAS G12D
drug discovery.
References
Timar J, Kashofer K (2020) Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer and Metastasis Reviews, 39(4):1029-1038, DOI:10.1007/s10555-020-09915-5.
Simanshu DK, Nissley DV, McCormick F (2017) RAS Proteins and Their Regulators in Human Disease. Cell, 170(1):17-33, DOI:10.1016/j.cell.2017.06.009.
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 503(7477):548-551, DOI:10.1038/nature12796.
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781):217-223, DOI:10.1038/s41586-019-1694-1.
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT (2020) KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 383(13):1207-1217, DOI:10.1056/NEJMoa1917239.
Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA (2020) Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 63(13):6679-6693, DOI:10.1021/acs.jmedchem.9b02052.
Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, Hallin J, Laguer J, Lawson JD, Medwid J, Newhouse B, Nguyen P, O'Leary JM, Olson P, Pajk S, Rahbaek L, Rodriguez M, Smith CR, Tang TP, Thomas NC, Vanderpool D, Vigers GP, Christensen JG, Marx MA (2022) Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. Journal of Medicinal Chemistry, 65(4):3123-3133, DOI:10.1021/acs.jmedchem.1c01688.
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, Pham H, Rahbaek L, Gunn RJ, Smith CR, Christensen JG, Olson P (2022) Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine, 28(10):2171-2182, DOI:10.1038/s41591-022-02007-7.
Du Z, Tu G, Gong Y, Fu X, Wu Q, Long G (2024) Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations. Molecules, 29(6):1229, DOI:10.3390/molecules29061229.
Issahaku AR, Mukelabai N, Agoni C, Rudrapal M, Aldosari SM, Almalki SG, Khan J (2022) Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Scientific Reports, 12:17796, DOI:10.1038/s41598-022-22668-1.
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2):455-461, DOI:10.1002/jcc.21334.
Tinkov OV, Gurevich PE, Nikolenko SA, Kadyrov SD, Bogatyreva NS, Grigorev VY, Ivankov DN, Pak MA (2026) KRASAVA-An Expert System for Virtual Screening of KRAS G12D Inhibitors. International Journal of Molecular Sciences, 27(1):120, DOI:10.3390/ijms27010120.
Abraham MJ, Murtola T, Schulz R, Pall S, Smith JC, Hess B, Lindahl E (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2:19-25, DOI:10.1016/j.softx.2015.06.001.
Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T (2019) End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chemical Reviews, 119(16):9478-9508, DOI:10.1021/acs.chemrev.9b00055.
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5):449-461, DOI:10.1517/17460441.2015.1032936.
Cournia Z, Allen B, Sherman W (2017) Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations. Journal of Chemical Information and Modeling, 57(12):2911-2937, DOI:10.1021/acs.jcim.7b00564.
Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, Shang Y, Zhang L, Li X, Zhang Y, Du Y, Chen CC, Guo RT, Zhang Y (2022) KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery, 8:5, DOI:10.1038/s41421-021-00368-w.
Yoshinari T, Nagashima T, Ishioka H, et al. (2025) Discovery of KRAS(G12D) selective degrader ASP3082. Communications Chemistry, 8:254, DOI:10.1038/s42004-025-01662-4.
Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, Wunberg T, Zoephel A, Fu SC, Teh J, Bottcher J, et al. (2021) BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discovery, 11(1):142-157, DOI:10.1158/2159-8290.CD-20-0142.
